Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference [Yahoo! Finance]
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Yahoo! Finance
CD388 was granted Fast Track Designation by the FDA in June 2023, and a Phase 2b trial was initiated in September 2024. Additionally, Cidara has developed other DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024. Investors interested in meeting with Cidara at the conference should contact their Evercore representative directly. A webcast of the presentation will be available at https://wsw.com/webcast/evercore44/cdtx/2373273, and a replay of the presentation will be available in the Investors section on Cidara's website at www.cidara.com for 90 days. Cidara Therapeutics is using its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs), and their lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose. SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics Announces $105 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Announces $105 Million Private PlacementGlobeNewswire
- Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx ConferenceGlobeNewswire
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CDTX
Earnings
- 11/7/24 - Beat
CDTX
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 8-K
- 11/7/24 - Form 10-Q
- CDTX's page on the SEC website